Stockscreener 앱 받기
307.08
4.58%
13.44
시장 영업 전:
310.49
3.41
+1.11%
전일 마감가:
$293.64
열려 있는:
$293.23
하루 거래량:
481.45K
Relative Volume:
1.09
시가총액:
$6.70B
수익:
-
순이익/손실:
$-518.67M
주가수익비율:
-12.22
EPS:
-25.12
순현금흐름:
$-438.32M
1주 성능:
+12.02%
1개월 성능:
-0.44%
6개월 성능:
+6.91%
1년 성능:
+35.59%
1일 변동 폭
$282.88
$308.46
1주일 범위
$266.44
$308.46
52주 변동 폭
$168.25
$368.29
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
MDGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
307.08 | 6.70B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 개시 | BofA Securities | Underperform |
| 2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 재확인 | Oppenheimer | Outperform |
| 2022-12-19 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-19 | 재확인 | Piper Sandler | Overweight |
| 2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-11-24 | 재개 | Evercore ISI | Outperform |
| 2020-11-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-01-30 | 개시 | Canaccord Genuity | Buy |
| 2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
| 2019-11-07 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-12-12 | 개시 | B. Riley FBR | Neutral |
| 2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 개시 | Citigroup | Buy |
| 2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Equities Analysts Issue Forecasts for MDGL FY2025 Earnings - MarketBeat
MDGL (Madrigal Pharmaceuticals) Dividends per Share : $0.00 (TTM As of Sep. 2024) - GuruFocus.com
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales - MSN
MDGL (Madrigal Pharmaceuticals) Change In Working Capital : $7.82 Mil (TTM As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals gains amid takeover speculation - MSN
MDGL (Madrigal Pharmaceuticals) Quick Ratio : 5.93 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH - Seeking Alpha
Have Insiders Sold Madrigal Pharmaceuticals Shares Recently? - Simply Wall St
MDGL (Madrigal Pharmaceuticals) Net Income From Continuing Operations : $-518.67 Mil (TTM As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) EV-to-EBITDA : -10.99 (As of Jan. 19, 2025) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Capex-to-Operating-Cash-Flo - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Earnings Yield % : N/A% (As of Jan. 19, 2025) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) 3-Year Book Growth Rate : 9.60% (As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Debt-to-Asset : 0.11 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals executive sells shares worth $120,847 - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Robert E. Waltermire Sells 442 Shares - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells $461,789.49 in Stock - MarketBeat
Madrigal Pharmaceuticals exec sells $461,789 in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals general counsel sells $75,734 in stock By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals general counsel sells $75,734 in stock - Investing.com India
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Up 7.4%Should You Buy? - MarketBeat
Madrigal Pharmaceuticals exec sells $461,789 in stock - Investing.com India
Shannon T. Kelley Sells 277 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock - MarketBeat
Madrigal Pharmaceuticals executive sells shares worth $120,847 By Investing.com - Investing.com Canada
Madrigral Pharmaceuticals gains amid takeover speculation - MSN
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week - MSN
Madrigal Reports Robust 2024 Performance and Plans for Growth - MSN
Why Madrigal Pharmaceuticals (MDGL) Stock is Moving Today - GuruFocus.com
What is HC Wainwright's Forecast for MDGL FY2024 Earnings? - MarketBeat
Hennion & Walsh Asset Management Inc. Reduces Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Trend Tracker for (MDGL) - Stock Traders Daily
Madrigal CEO touts 'amazing' sales success of new MASH drug, but stock slumps - The Business Journals
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Down 14.4%Here's What Happened - MarketBeat
Why Madrigal Pharmaceuticals Stock Is Sinking Today - MSN
Madrigal Pharmaceuticals Enters Oversold Territory (MDGL) - Nasdaq
HC Wainwright Issues Positive Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price - MarketBeat
Madrigal Pharmaceuticals' SWOT analysis: Rezdiffra success drives stock outlook By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals' SWOT analysis: Rezdiffra success drives stock outlook - Investing.com India
MDGL Stock Dips Amid Preliminary 2024 Results Release - GuruFocus.com
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra - The Manila Times
Madrigal's Rezdiffra Achieves $180M Sales in First Year as Groundbreaking MASH Treatment - StockTitan
Madrigal Pharmaceuticals' SWOT analysis: stock poised for growth amid NASH market potential - Investing.com India
Madrigal Pharmaceuticals’ SWOT analysis: stock poised for growth amid NASH market potential - Investing.com Nigeria
Madrigal Pharmaceuticals' SWOT analysis: stock poised for growth amid NASH market potential By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):